OnKure Q2 2026 net loss $15.3M; cash $176.4M funds operations into 2029

OnKure Therapeutics, Inc.

2026-Q2 EPS reported -$0.96

Net loss of $15.3M ($0.31 per share) vs $15.4M ($1.14 per share) in Q2 2025.
Cash, cash equivalents and marketable securities of $176.4M as of June 30, 2026; runway into 2029.
R&D expenses flat at $12.6M; G&A up $0.6M to $4.3M on higher personnel and consulting costs.
IND submissions for PI3Kα pan-mutant candidates OKI-345 (breast cancer) and OKI-355 (vascular anomalies) planned for 1H 2027.
Hosted KOL event on PI3Kα selectivity; participated as exhibitor/sponsor at ISSVA World Congress 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.